William R. Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William R. Zhang has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey P. North
Department of Pathology and Dermatology University of California San Francisco San Francisco California USA
2 shared publications Tina Bhutani
Department of Dermatology University of California San Francisco California USA
2 shared publicationsJoshua M. Schulman
Department of Dermatology University of California Davis Sacramento California USA
1 shared publication
Latest Publications
- 8 October 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 52 (1) , 48-53
The Association of Interleukin‐36 Staining Intensity and Response to Biologic Therapy in Patients With Psoriasis: A Retrospective Immunohistochemical and Chart Review Pilot Study
Background: There are limited surrogate biomarkers to identify the active inflammatory pathway in psoriasis to direct treatment with targeted biologic therapies. We investigated the association of interleukin (IL)‐36 epidermal expression, a diagnostic marker of psoriasis, with response to biologic therapy in patients with psoriasis.Methods: Retrospective immunohistochemical and chart review pilot study.Results: Patients with psoriasis with low (scores 0–2) vs. high (scores 3–4) IL‐36 expression did not have significantly different response rates to tumor necrosis factor α (TNFα), IL‐17, and IL‐12/23 or IL‐23 inhibitors; and similarly, mean IL‐36 expression scores did not significantly differ among responders vs. non‐responders to each treatment mechanism. However, in patients with psoriasis treated with IL‐12/23 or IL‐23 inhibitors, there was a marked absolute difference in response rates in those with high vs. low IL‐36 (84% vs. 50%, p = 0.12) and in mean IL‐36 scores in responders vs. non‐responders (3.35 vs. 2.57, p = 0.19).Conclusions: Patients with psoriasis with high IL‐36 expression were more likely to respond to IL‐12/23 and IL‐23 inhibition than those with low IL‐36, though these findings were not statistically significant. Additional studies with larger sample sizes are needed to validate and expand upon these findings.
- 8 October 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 52 (1) , 48-53
The Association of Interleukin‐36 Staining Intensity and Response to Biologic Therapy in Patients With Psoriasis: A Retrospective Immunohistochemical and Chart Review Pilot Study
Background: There are limited surrogate biomarkers to identify the active inflammatory pathway in psoriasis to direct treatment with targeted biologic therapies. We investigated the association of interleukin (IL)‐36 epidermal expression, a diagnostic marker of psoriasis, with response to biologic therapy in patients with psoriasis.Methods: Retrospective immunohistochemical and chart review pilot study.Results: Patients with psoriasis with low (scores 0–2) vs. high (scores 3–4) IL‐36 expression did not have significantly different response rates to tumor necrosis factor α (TNFα), IL‐17, and IL‐12/23 or IL‐23 inhibitors; and similarly, mean IL‐36 expression scores did not significantly differ among responders vs. non‐responders to each treatment mechanism. However, in patients with psoriasis treated with IL‐12/23 or IL‐23 inhibitors, there was a marked absolute difference in response rates in those with high vs. low IL‐36 (84% vs. 50%, p = 0.12) and in mean IL‐36 scores in responders vs. non‐responders (3.35 vs. 2.57, p = 0.19).Conclusions: Patients with psoriasis with high IL‐36 expression were more likely to respond to IL‐12/23 and IL‐23 inhibition than those with low IL‐36, though these findings were not statistically significant. Additional studies with larger sample sizes are needed to validate and expand upon these findings.
- 31 August 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 52 (4) , 251-253
The association of interleukin‐36 staining intensity with histopathologic findings of eosinophil count and spongiosis in patients with psoriasis: A secondary analysis of a retrospective immunohistochemical and chart review pilot study
- 31 August 2024
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 52 (4) , 251-253
The association of interleukin‐36 staining intensity with histopathologic findings of eosinophil count and spongiosis in patients with psoriasis: A secondary analysis of a retrospective immunohistochemical and chart review pilot study